Scientific American spotlights keto's promise for mental health treatment

Keto’s move from weight loss to psychiatry is attracting real scientific attention because the early signals are starting to line up across different clinics. The promise is most striking in schizophrenia, bipolar disorder and treatment-resistant depression, but the central message from researchers is still caution: this is emerging metabolic psychiatry, not a green light for DIY keto as a mental health fix.

Stanford Medicine helped sharpen that case in a four-month pilot study of 21 adults with schizophrenia or bipolar disorder who also had metabolic abnormalities. The diet, published March 27, 2024 in Psychiatry Research, was built around roughly 10% carbohydrates, 30% protein and 60% fat, and Stanford said participants saw improvements in both metabolic health and psychiatric symptoms. That matters because antipsychotic medications can worsen weight gain, insulin resistance, dyslipidemia and glucose tolerance, making adherence harder for people who already face serious illness. Stanford also says metabolic syndrome may affect as many as one in three Americans.

The idea behind metabolic psychiatry is that some mental health conditions may be tied to deeper problems in brain energy metabolism, inflammation, insulin resistance and mitochondrial function. That framework has given new life to a therapy that is not new at all. Stanford points back more than 100 years, to endocrinologist Russell Wilder’s 1921 work on epilepsy, as a reminder that ketogenic therapy has long been used for neurological disease under clinical supervision, not as an internet challenge.

Advocacy has also pushed the topic into the mainstream. Mikhaila Peterson and Jan Ellison Baszucki have both highlighted diet-based approaches to mental health, while Baszucki, founder of Metabolic Mind and president of the Baszucki Group, has helped fund education and research in the space. Shebani Sethi is now recruiting for a larger randomized controlled trial to test ketogenic therapy’s effect on quality of life for people with schizophrenia, bipolar disorder and depression.

The newest studies help explain the momentum, but they also show how much work remains. In 2026, a randomized clinical trial in 88 adults in the United Kingdom with treatment-resistant depression found that the ketogenic group improved more on PHQ-9 scores at six weeks than the control-diet group, even though both groups improved and the 12-week difference was not statistically significant. Another 2026 pilot in adults with anorexia nervosa tested a 14-week weight-maintaining ketogenic therapy in 22 participants, with 18 completing the study, or 82 percent. The field is moving fast, but the evidence still says the same thing twice: encouraging signals, careful supervision, and no shortcuts.